In the hopes of ensuring our ability to grow even further in this direction, in February of 2004 we merged with DVx Japan K.K. Inc. and changed our name to DVx Inc. This move was driven by two major desires.
First, we hoped to expand beyond our traditional strength in providing products and services in the area of arrhythmia management and enter the field of ischemia therapy as well, continuing to pursue new challenges in areas beyond those where we could leverage the synergies between them.
Second, we wanted to expand beyond our role as a reseller focused on metropolitan Tokyo by expanding our business both regionally and functionally so that we could act as a bridge between patients, physicians, and resellers nationwide. Our ambition was to make a major contribution by bringing these parties together with medical technology from around the world.
To ensure the success of these aspirations to take on new fields and contribute as a bridge, in April of 2007 we went public on the JASDAQ securities exchange (now part of the Tokyo Stock Exchange). In December of 2013, our stock was listed on the second section of the Tokyo Stock Exchange, and in September of 2014, upgraded to the first section of the Tokyo Stock Exchange.
Going forward, we hope to continue growing, not only to achieve the ambitions we've nurtured since our founding, but to fulfill our even greater responsibility to society as a public company.
We look forward to your honest input and wisdom as we continue to pursue these goals.
To further reinforce our existing business, and to quickly put our efforts in new fields on a solid footing, we will actively seek out and consider your input as we continue to take on new challenges.
